252 related articles for article (PubMed ID: 33025535)
41. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease.
Moretti M
Expert Rev Respir Med; 2007 Dec; 1(3):307-16. PubMed ID: 20477170
[TBL] [Abstract][Full Text] [Related]
42. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
43. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease.
Marchioni CF; Moretti M; Muratori M; Casadei MC; Guerzoni P; Scuri R; Fregnan GB
Lung; 1990; 168(5):285-93. PubMed ID: 2126836
[TBL] [Abstract][Full Text] [Related]
44. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats.
Yildirim Z; Turkoz Y; Kotuk M; Armutcu F; Gurel A; Iraz M; Ozen S; Aydogdu I; Akyol O
Nitric Oxide; 2004 Sep; 11(2):156-65. PubMed ID: 15491848
[TBL] [Abstract][Full Text] [Related]
45. Effects of erdosteine and its metabolites on bacterial adhesiveness.
Braga PC; Dal Sasso M; Sala MT; Gianelle V
Arzneimittelforschung; 1999 Apr; 49(4):344-50. PubMed ID: 10337454
[TBL] [Abstract][Full Text] [Related]
46. Erdosteine protects HEI-OC1 auditory cells from cisplatin toxicity through suppression of inflammatory cytokines and induction of Nrf2 target proteins.
Kim SJ; Park C; Lee JN; Lim H; Hong GY; Moon SK; Lim DJ; Choe SK; Park R
Toxicol Appl Pharmacol; 2015 Oct; 288(2):192-202. PubMed ID: 26193055
[TBL] [Abstract][Full Text] [Related]
47. Effects on the reactive oxygen species of erdosteine and its metabolite in vitro.
Hosoe H; Kaise T; Ohmori K
Arzneimittelforschung; 2002; 52(6):435-40. PubMed ID: 12109043
[TBL] [Abstract][Full Text] [Related]
48. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis.
Olivieri D; Del Donno M; Casalini A; D'Ippolito R; Fregnan GB
Respiration; 1991; 58(2):91-4. PubMed ID: 1862257
[TBL] [Abstract][Full Text] [Related]
49. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine.
Oktem F; Arslan MK; Ozguner F; Candir O; Yilmaz HR; Ciris M; Uz E
Toxicology; 2005 Nov; 215(3):227-33. PubMed ID: 16112787
[TBL] [Abstract][Full Text] [Related]
50. Erdosteine enhances mucociliary clearance in rats with and without airway inflammation.
Hosoe H; Kaise T; Ohmori K
J Pharmacol Toxicol Methods; 1998 Oct; 40(3):165-71. PubMed ID: 10334633
[TBL] [Abstract][Full Text] [Related]
51. Antioxidants and mucolytics in COPD management: when (if ever) and in whom?
Hillas G; Nikolakopoulou S; Hussain S; Vassilakopoulos T
Curr Drug Targets; 2013 Feb; 14(2):225-34. PubMed ID: 23256719
[TBL] [Abstract][Full Text] [Related]
52. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
53. Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats.
Sogut S; Ozyurt H; Armutcu F; Kart L; Iraz M; Akyol O; Ozen S; Kaplan S; Temel I; Yildirim Z
Eur J Pharmacol; 2004 Jun; 494(2-3):213-20. PubMed ID: 15212977
[TBL] [Abstract][Full Text] [Related]
54. Antioxidant therapeutic targets in COPD.
Rahman I; Kilty I
Curr Drug Targets; 2006 Jun; 7(6):707-20. PubMed ID: 16787173
[TBL] [Abstract][Full Text] [Related]
55. Mucolytic and antitussive effects of erdosteine.
Hosoe H; Kaise T; Ohmori K; Isohama Y; Kai H; Takahama K; Miyata T
J Pharm Pharmacol; 1999 Aug; 51(8):959-66. PubMed ID: 10504037
[TBL] [Abstract][Full Text] [Related]
56. Erdosteine ameliorates neurological outcome and oxidative stress due to ischemia/reperfusion injury in rabbit spinal cord.
Ege E; Ilhan A; Gurel A; Akyol O; Ozen S
Eur J Vasc Endovasc Surg; 2004 Oct; 28(4):379-86. PubMed ID: 15350559
[TBL] [Abstract][Full Text] [Related]
57. Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model.
Karateke A; Dokuyucu R; Dogan H; Ozgur T; Tas ZA; Tutuk O; Agturk G; Tumer C
Med Princ Pract; 2018; 27(6):515-522. PubMed ID: 30293079
[TBL] [Abstract][Full Text] [Related]
58. Effects of erdosteine on cyclosporin-A-induced nephrotoxicity.
Tutanc M; Arica V; Yılmaz N; Nacar A; Zararsiz I; Basarslan F; Tutanc OD; Nacar E
Hum Exp Toxicol; 2012 Jun; 31(6):565-73. PubMed ID: 21813577
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study).
Marchioni CF; Polu JM; Taytard A; Hanard T; Noseda G; Mancini C
Int J Clin Pharmacol Ther; 1995 Nov; 33(11):612-8. PubMed ID: 8688986
[TBL] [Abstract][Full Text] [Related]
60. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
